Precision BioSciences Secures $13 Million in Funding to Advance Gene Editing Innovations

Precision BioSciences, Inc. (Nasdaq: DTIL), a pioneering pre-clinical stage gene editing company based in Durham, North Carolina, has successfully raised $13 million to advance its innovative gene editing technologies. This funding will be instrumental in further developing the company's ARCUS genome editing platform, which harnesses sequence-specific DNA-cutting enzymes, also known as nucleases. These advanced tools enable not just precise gene knockouts, but also complex modifications such as gene insertion and repair. The successful funding round underscores investor confidence in Precision BioSciences' breakthrough potential to revolutionize the field of gene therapy through its versatile technology. The company aims to leverage this investment to propel its ongoing research and accelerate the development of targeted treatments for genetic disorders. As global interest in gene editing and its therapeutic applications continues to surge, Precision BioSciences is strategically positioned to make significant contributions to medical advancements that could improve or even save countless lives. The funding will support key initiatives, expanding pre-clinical studies and enhancing collaborations with academic institutions and industry partners to broaden the scope of ARCUS applications. Precision BioSciences remains committed to transforming the potential of gene editing into tangible solutions that address unmet medical needs. For more information about Precision BioSciences and its groundbreaking work in gene editing, visit www.precisionbiosciences.com.